**SAMPLE PUBLICATIONS**

* Collins DC, Cocchiglia S, Tibbitts P, Solon G, Bane FT, McBryan J, Treumann A, Eustace A, Hennessy B, Hill AD, Young LS. [Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/24469058)

 Oncogene. 2014 Jan 27. doi: 10.1038/onc.2013.586.

* [AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.](http://www.ncbi.nlm.nih.gov/pubmed/22550166)

O'Hara J, Vareslija D, McBryan J, Bane F, Tibbitts P, Byrne C, Conroy RM, Hao Y, Gaora PÓ, **Hill AD**, McIlroy M, **Young** LS.

Clin Cancer Res. 2012 Jun 15;18(12):3305-15. doi: 10.1158/1078-0432.CCR-11-3300. Epub 2012 May 1.

* McBryan J, Theissen SM, Byrne C, Hughes E, Cocchiglia S, Sande S, O'Hara J, Tibbitts PS, Hill A, Young L. .
[Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1.](http://www.ncbi.nlm.nih.gov/pubmed/22108824)
Cancer Res. 2011 Nov 22. [Epub ahead of print]     PMID: 22108824      (Nov 2011)
* McCartan D, Bolger J, Fagan A, Byrne C, Hao Y, Qin L, McIlroy M, Xu J, Hill A, O Gaora P, Young L. .
[Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine resistant breast cancer.](http://www.ncbi.nlm.nih.gov/pubmed/22072566)
Cancer Res. 2011 Nov 16. [Epub ahead of print]     PMID: 22072566      (Nov 2011)
* Flavin P, Redmond A, McBryan J, Cocchiglia S, Tibbitts P, Fahy-Browne P, Kay E, Treumann A, Perrem K, McIlroy M, Hill AD, Young LS. .
[RuvBl2 cooperates with Ets2 to transcriptionally regulate hTERT in colon cancer.](http://www.ncbi.nlm.nih.gov/pubmed/21763315)
FEBS Lett. 585(15):2537-44.     PMID: 21763315      (Aug 2011)
* deBlacam C, Byrne C, Hughes E, McIlroy M, Bane F, Hill AD, Young LS. .
[HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib.](http://www.ncbi.nlm.nih.gov/pubmed/21654685)
105(1):118-23.     PMID: 21654685      (Jun 2011)
* Al-azawi D, Leong S, Wong L, Kay E, Hill AD, Young L. .
[HER-2 positive and p53 negative breast cancers are associated with poor prognosis.](http://www.ncbi.nlm.nih.gov/pubmed/21599513)
29(5):365-9.     PMID: 21599513      (Jun 2011)
* Caiazza F, McCarthy NS, Young L, Hill AD, Harvey BJ, Thomas W. .
[Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours.](http://www.ncbi.nlm.nih.gov/pubmed/21119660)
Br J Cancer. 104(2):338-44.     PMID: 21119660      (Jan 2011)